drugset
drugset / Trial / NCT03109158

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT03109158 ↗

Phase 1/2 Completed 1 enrolled NanoCarrier Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Part 1 of this study will establish a recommended Phase II (RPII) dose for the triplet combination of NC-6004 plus 5-Fluorouracil (5-FU) and cetuximab. Part 2 will provide the efficacy signal of the triplet combination in this patient population.

Timeline

Start
2017-03-01
Primary completion
2019-03-01
Completion
2019-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified — —
Background Cetuximab Monoclonal antibody — —
Background fluorouracil Small molecule — —

Indications

head and neck squamous cell carcinoma